Eli Lilly & Co. has unveiled a new formulation of its popular obesity treatment, Zepbound, introducing a multi-dose injection pen known as the KwikPen. This device, designed for cash-paying patients, allows users to administer a month’s worth of doses from a single pen, as opposed to the previous requirement of using a separate device each week.
Available for purchase on Lilly’s direct-to-consumer platform, LillyDirect, the KwikPen is priced starting at $299 per month for the lowest dosage. This innovative device streamlines the treatment process, enabling patients to take four weekly doses of Zepbound without the hassle of multiple auto-injectors. Previously, users had to utilize a single-dose device each week or draw medication from vials into syringes for self-injection.
The launch of the KwikPen coincides with a surge in demand for Zepbound, which has significantly increased Eli Lilly’s market presence in the weight loss sector since its debut in late 2023. The direct-to-consumer initiative, LillyDirect, has played a pivotal role in this growth, and the introduction of the new device on the platform aims to attract additional patients.
In the last quarter, Zepbound generated an impressive $4.2 billion in U.S. revenue, marking a 122% increase compared to the previous year. The recent approval from the Food and Drug Administration for the label expansion to include the multi-dose device highlights Lilly’s commitment to providing accessible solutions for patients managing obesity.
The KwikPen format is not entirely new; it is already utilized for other Eli Lilly medications, including the diabetes treatment, Mounjaro. Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, emphasized the company’s dedication to supporting individuals in their weight management journey, stating that the new KwikPen offers a trusted option for patients both in the U.S. and globally.
